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Background: Hepatic ischaemia–reperfusion (I/R) injury occurs in both liver resectional surgery and in
transplantation. The biochemistry of I/R injury involves short-lived oxygen free radicals. N-acetylcysteine
(NAC) is a thiol-containing synthetic compound used in the treatment of acetaminophen toxicity. The
present study is a detailed overview of the experimental and clinical evidence for the use of NAC as a
pharmaco-protection agent in patients undergoing major liver surgery or transplantation.
Methods: A computerized search of the Medline, Embase and SCI databases for the period from 1st
January 1988 to 31st December 2008 produced 40 reports. For clinical studies, the quality of reports was
assessed according to the criteria reported by the Cochrane communication review group.
Results: Nineteen studies evaluated NAC in experimental liver I/R injury. NAC was administered before
induction of ischaemia in 13. The most widely used concentration was 150 mg/kg by intravenous bolus.
Fifteen studies report an improvement in outcome, predominantly a reduction in transaminase. Seven
studies used an isolated perfused liver model with all showing improvement (predominantly an improve-
ment in bile production after N-acetylcysteine). Two out of four transplantation models showed an
improvement in hepatic function. Clinical studies in transplantation show a modest improvement in
transaminase levels with no beneficial effect on either patient or graft survival.
Conclusion: N-acetylcysteine, given before induction of a liver I/R injury in an experimental model can
ameliorate liver injury. Clinical outcome data are limited and there is currently little evidence to justify use
either in liver transplantation or in liver resectional surgery.
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Introduction
Hepatic ischaemia followed by reperfusion occurs both during
liver resectional surgery and during liver transplantation. Liver
transplantation is further characterized by periods of cold and
warm ischaemia. Both contribute to hepatic ischaemic injury.
This ischaemia–reperfusion (I/R) injury has effects on post-
operative liver function and remote organ injury and is thought
to be influential in post-operative recovery and eventual clinical
outcome.1,2
Restoration of blood flow results in a series of events that exac-
erbate the ischaemic injury.3 Interactions between hepatic sinusoi-
dal endothelium, hepatic Kupffer cells and the cellular and soluble
messenger components of blood inflow results in the production of
local injury and a systemic inflammatory response. At the hepato-
cellular level, short-lived intracellular oxygen-free radicals are pro-
duced primarily by the mitochondria as a by-product of normal
metabolism. In addition to central mechanisms in cellular homeo-
stasis, they are known to have roles in intracellular signalling and
gene expression.4 Oxygen-free radicals are by convention described
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as mediators of oxidative stress. Over-activity of these oxygen-free
radicals (either because of excess production or inadequate
quenching) leads to cellular injury – a process termed oxidative
injury.
The intra-cellular defence mechanisms involved in the regu-
lation of oxidative stress are well recognized and involve enzy-
matic pathways catalyzed by superoxide dismutase and
glutathione peroxidise.5 Glutathione (GSH), a tri-peptide com-
posed of glycine, glutamic acid and cysteine, is the most abun-
dant non-protein sulfhydryl-containing compound and
constitutes the largest component of the endogenous thiol buffer
involved in removal of oxygen-free radicals.6 For tissue GSH syn-
thesis, the availability of cysteine is generally the limiting factor.
A potentially important cysteine precursor is N-acetylcysteine.7
N-acetylcysteine (NAC) is a thiol-containing synthetic com-
pound. Unlike GSH, NAC readily diffuses into cells and hydro-
lyzes into L-cysteine and this in turn replenishes depleted stores
of GSH. Currently the most established clinical use for NAC is in
the treatment of acetaminophen (Paracetamol) poisoning to
prevent fulminant hepatic failure.8,9 There is a large body of
clinical data for using NAC in patients with acetaminophen
toxicity.8–11
Given this role in the treatment of drug-induced liver injury,
there is a case for evaluation of NAC in surgically-induced liver
I/R injury, both in terms of hepatic resection and liver transplan-
tation. To this end, there is a substantial body of experimental
work evaluating the role of NAC in liver I/R injury. Individually,
these studies are small and utilize a widely disparate range of
protocols.
The aim of the present study was to provide a concise overview
of the experimental and clinical evidence for the use of NAC as a
pharmaco-protection agent to reduce liver injury in patients
undergoing major liver surgery.
Methods
Literature search
A computerized search was performed of the Medline and
Embase databases for the period from 1st January 1988 to 31st
December 2008 using the OVID search engine (Ovid Technolo-
gies, Inc., New York, NY, USA; Version: rel10.5.1, Source ID
1.13281.2.21). The Science Citation Index (SCI) was also
searched using the ISI Web of Knowledge (v.4.9). The keywords
liver or hepat#, surgery, resection, hepatectomy, transplant, seg-
mentectomy, ischae$, ische$, reperfusion were used and the
results were combined with N-acetylcysteine, acetylcysteine, par-
volex, flumucil and acetadole. This search yielded 484 citations.
Exclusion of repeat articles produced a list of 270 citations. The
abstracts of these 270 articles were examined to exclude reviews,
case reports, articles un-related to the use of NAC in liver
surgery, duplicate publications, articles providing no
original data and non-English language publications. This pro-
duced a population of 36 reports. Manual cross-referencing of
the bibliography of these articles yielded a further four
reports. These 40 reports constitute the final study population.
The article selection process is summarised in figure 1. The
Cochrane Database of Systematic Reviews was then cross-checked
to confirm that no similar reviews have already been undertaken.
Data quality and extraction
Experimental studies are reported with reference to species,
experimental model, NAC intervention protocol and principal
outcomes.
For clinical studies, the quality of reports included was
assessed according to the criteria reported in the study quality
guide reported by the Cochrane consumers and communication
review group (http://www.latrobe.edu.au/cochrane/resources.
html).12 In brief, studies were assessed on seven criteria: validity
of randomization, concealment of allocation, blinding, baseline
comparability, follow-up, intention-to-treat analysis and valida-
tion of tools.
Potentially relevant studies
identified by searching
electronic databases (n = 484)
Excluding multiple hits
(n = 214)
Studies retrieved for more
detailed evaluation (n = 270)
Potentially appropriate studies
to be included in the review
(n = 36)
Final study population
(n = 40) 
Studies excluded - reviews, case
reports, no original data,
multiple publications, unrelated
and non-English language
publications (n = 234)
Manual cross referencing of the
bibliography (n = 4)
Figure 1 QUORUM flowchart
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Results
Experimental studies evaluating NAC in liver I/R
injury (n = 19)
Nineteen studies evaluating the role of NAC in experimental liver
I/R injury are summarized in Table 1.13–31 No studies reported the
use of sample power calculations. A wide range of experimental
animals and protocols are reported. NAC was administered before
induction of ischaemia in 13 studies14–16,19,21–23,25,27–31 and in 3
studies17,20,24 after the ischaemic event but before or during
re-perfusion. In three studies13,18,26 NAC was administered before
and after ischaemia and re-perfusion.
The most widely used concentration of NAC in these studies
was 150 mg/kg (range 20 to 500 mg/kg) given by intravenous (i.v.)
bolus.
In terms of effect of NAC on endpoints, 15 (79%) of the 19
studies reported a beneficial effect of intervention on outcome. A
wide range of endpoints were utilized. Seven of the studies that
reported a beneficial effect used plasma levels of transaminases
and/or acute phase proteins such as tumour necrosis factor-alpha
(TNF-a) as surrogate endpoints for reduction in I/R
injury.13,15,18,23,25,27,31 Three of the studies that reported a beneficial
effect of NAC reported an improvement in hepatic microcircula-
tion.14,20,24 A reduction of free radicals was reported in two stud-
ies.17,26 A reduction in bacterial growth in lymphatic tissue and
bacterial translocation in the intestine was reported in two stud-
ies.22,28 The study by Galhardo et al.29 showed that NAC reduced
hepatic necrosis and pulmonary oedema.
Four studies showed no benefit of NAC on markers of liver I/R
injury.16,19,21,30 These negative studies included protocols which
involved administration of NAC before induction of ischaemia.
The study by Rudiger et al. 19 is of particular interest in that they
demonstrated that NAC inhibited the oxidative burst of ischaemic
pre-conditioning and reversed the protective effects associated
with pre-conditioning.
Experimental studies evaluating NAC in the isolated
perfused liver (n = 7)
Seven studies evaluating the role of NAC in an isolated perfused
liver model are summarized in Table 2.32–38 All isolated perfused
studies followed a protocol of prolonged cold storage before iso-
lated perfusion of the liver. This was either 24 (4 studies) or 48 h
(3 studies). The period of isolated perfusion ranged from 60 to
180 min. All the studies administered NAC before hepatectomy,
but the route of administration varied. In five studies34–38 NAC was
administered intraportally or via the superior mesenteric vein.
The remaining two studies used the intraperitoneal and subcuta-
neous routes, respectively.
The most frequently used concentration was 150 mg/kg (range-
100–150 mg initial dose). In terms of the effect of NAC on end-
points all seven studies showed some beneficial effects of NAC in
amelioration of liver injury. Bile production by the isolated per-
fused liver was a principle outcome in five out of the seven
studies32,33,36–38 with all reporting improved bile production.
Nakano et al. showed that NAC enhanced hepatocyte cysteine and
had a protective effect on hepatic Kupffer cells.34 Another study by
Nakano et al. is of interest as it showed that pre-ischaemia admin-
istration of NAC attenuated hepatic injury but that the protective
effect was lost when NAC was given at reperfusion.35
Experimental studies evaluating NAC in liver
transplantation (n = 4)
Four studies evaluating the role of NAC in experimental liver
transplantation are summarized in Table 3.39–42 Two studies used a
rat39,40 model and two utilized a porcine41,42 model. Both rat
models utilized periods of storage of the explanted liver in cold
university of Wisconsin solution before transplantation (20 and
24 h, respectively). The timing of administration and the dose of
NAC varied between the four studies. The dose given to the donor
varied from 150 mg/kg to 3 g/kg. In three studies NAC was given
to the both donor and recipient.39,40,42 Two studies showed no
beneficial effects of NAC on outcome after liver transplanta-
tion.39,42 Two studies showed some beneficial effects.40,41 The ben-
eficial effects included a reduction in non-perfused sinusoids40
and a reduction in transaminase associated with improved pro-
duction of coagulation factors and better survival.41
Clinical studies evaluating NAC in liver
transplantation (n = 9)
Nine clinical trials evaluating the role of NAC in liver transplan-
tation are summarized in Table 4.43–51 The total of all patients
allocated to treatment arms is 175 [mean number of patients per
study = 19 (range 9–30)]. Six studies are randomized controlled
trials and the majority reported biochemical endpoints. Applying
contemporary assessment criteria, these studies failed to
adequately report their methods of randomization, concealment
and blinding. Baseline comparability is acceptable and the results
are reported on an intention-to-treat basis (except in one).
Follow-up is complete but is short term.
There was variation in the approach to administration of NAC
with some studies administering the agent to the donor and others
to the recipient. Three studies44,45,47 reported a reduction in post-
operative liver enzymes. Three studies46,49,50 reported no difference
in post-operative liver enzymes. No studies showed a difference in
graft survival although the study by Bucuvalas et al.47 suggests that
rejection episodes were more severe in the patient group who did
not receive N-acetylcysteine. No studies showed any other differ-
ence in a clinically important endpoint in treatment groups.
Clinical studies evaluating NAC in liver
resection (n = 1)
To date, there is one small study, reported only in abstract form,
describing the outcome of a randomized controlled trial in
patients undergoing liver resection.52 Patients in the treatment
arm received NAC as an i.v. infusion (150 mg/kg loading dose
followed by 50 mg/kg over 4 h and 50 mg/kg over the subsequent
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Table 1 Design and key summary findings of experimental studies evaluating N-acetylcysteine in liver ischaemia-reperfusion (I/R)
injury (n = 19)
First author/year Species Experimental model NAC intervention Principal outcome
Fukuzawa et al.
199513
Pig 2 h warm ischaemia by hilar clamp
above portacaval shunt followed
by re-perfusion
150 mg/kg NAC (20% solution) in
0.09% saline, as continuous
infusion. Pre- and post-
ischaemia groups
Lower AST, LDH & higher ATP
content and bile output in
intervention groups.
Koeppel et al.
199614
Rat 70 min warm ischaemia (left lobe)
followed by reperfusion
400 mg/kg NAC intravenous
infusion 20 min before
ischaemia.
Improvement in hepatic
microcirculation.
Demir et al.
199815
Rat 30 min warm ischaemia (left &
median lobe) followed by
reperfusion
500 mg/kg NAC 20 min before
ischaemia (also a joint
pentoxifylline group)
NAC reduced markers of oxidative
injury.
No synergistic effect with
pentoxifylline.
Chavez-Cartaya
et al. 199916
Rat 45 min warm ischaemia (medial
and left lobe) followed by
reperfusion
300 mg/kg NAC as intramuscular
injection 30 min before
ischaemia.
No beneficial effect of NAC.
Hur et al. 199917 Rat 45 min median and left lateral lobe
warm ischaemia. Measurement
of iNOS gene expression.
20 mg/kg NAC bolus. 10 min
before reperfusion.
NAC inhibited expression of
iNOS mRNA & upregulated
NF-kB.
Sener et al.
199918
Rat 45 min warm ischaemia (total
hepatic ischaemia)
150 mg/kg NAC (also a joint
melatonin group) 15 before
ischemia and immediately before
reperfusion.
NAC reduced liver I/R injury.
Synergistic effect with melatonin.
Rudiger et al.
200319
Mouse 75 min warm ischaemia. Partial
and total ischaemia models.
100 mg/kg NAC pre-treatment. NAC reversed the protective
effects of preconditioning.
Glantzounis et al.
200420
Rabbit 60 min warm ischaemia followed
by 7 h reperfusion.
150 mg/kg NAC as intravenous
infusion prior to reperfusion.
Hepatic microcirculation improved.
Montero et al.
200521
Rat Warm ischaemia  ischaemic
preconditioning  selective
biliary exclusion
150 mg/kg NAC intravenous bolus
15 min before ischaemia.
No beneficial effect of NAC on liver
IR injury.
Okay et al.
200522
Rat Partial hepatectomy 400 mg/kg NAC intravenous bolus
before resection.
NAC attenuated bacterial
translocation and lung injury.
Smyrniotis et al.
200523
Rat 60 min warm ischaemia (medial
and left lobe)
300 mg/kg NAC intravenous bolus
prior to ischaemia.
Attenuates liver I/R, less platelet
aggregation, increases cAMP.
Fusai et al.
2005.24
Rabbit 60 min warm ischaemia of rabbit
median and left lobe.
150 mg/kg NAC intravenous
infusion prior to reperfusion.
NAC decreased I/R injury during
late reperfusion. Microcirculation
improved.
Chen et al.
200525
Rat 40 min warm ischaemia (total
hepatic ischaemia).
20 mg/kg NAC 20 min prior to
ischaemia.
Reduction in reperfusion induced
MMP9
Glantzounis et al.
200726
Rabbit. 60 min lobar ischaemia and 7 h
re-perfusion.
150 mg/kg NAC prior to and
during reperfusion.
NAC prevented increase in RNS
during reperfusion.
Jin et al. 200727 Mouse 60 min partial hepatic ischaemia.
Measurement of TLR 2 and 4.
Pre-treatment with 150 mg/kg NAC NAC inhibited the activation of
TLR2/4 and the induction of
TNFa.
Oz et al. 200728 Rat Partial hepatectomy (left anterior
and median lobe resection)
250 mg/kg NAC given prior to
resection.
Reduction in bacterial growth in
spleen and mesenteric lymph
nodes.
Galhardo et al.
200729
Rat 10 min ischaemic pre-condition +
40 min warm ischaemia
150 mg/kg NAC intravenous bolus
prior to ischaemia period.
NAC reduced hepatic necrosis and
pulmonary oedema.
Bauman et al.
200830
Dog 60 min warm ischaemia. 150 mg/kg NAC intravenous bolus
2 min prior to ischaemia.
No beneficial effect of NAC on liver
IR injury.
Keles et al.
200831
Rat 90 min left lobe ischaemia. 90 min
reperfusion.
250 mg/kg NAC bolus
pre-ischaemia.
NAC reduced 8-OHdG formation
and lipid peroxidation.
AST, aspartate aminotransferase; LDH, lactate dehydrogenase; ATP, adenosine triphosphate; iNOS, inducible nitric oxide synthase; NAC,
N-acetylcysteine; Nf-kB, nuclear factor kappa B; mRNA, messenger ribonucleic acid; cAMP, cyclic adenosine monophosphate; RNS, reactive nitrogen
species; MMP 9, matrix metalloproteinase 9; TLR 2, TLR 4, toll-like receptor 2 and toll-like receptor 4; TNF-a, tumour necrosis factor-alpha; 8-OHdG,
8-hydroxydeoxyguanosine.
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8 h). After excluding patients with operative findings of unresec-
table disease, 31 patients were randomized: 15 to NAC and 16 to
placebo. Endpoints showed a significant reduction in transami-
nase and a reduction in the number of patients having increased
expression of soluble intercellular adhesion molecule-1 (ICAM-
1). As the report is available in abstract form only, it is not possible
to comment further on the study. However, at the least, this is an
underpowered study with no mention of an a priori sample power
calculation.
In an indirectly related work, Szakmany et al.53 undertook a
randomized trial of the effect of prophylactic NAC on
post-operative organ dysfunction after major abdominal
surgery. Their study of 93 patients included 6 patients
undergoing liver resection. This manuscript is not in the 40
manuscript study population as it does not principally
address liver surgery or report discrete outcomes of NAC
in liver resection. It is retained as it does add to the published
experience on NAC in liver resection and is one of only
two studies in this area. Overall, Szakmany and colleagues
reported no difference in organ dysfunction, length of
critical care occupancy or mortality in patients receiving
N-acetylcysteine.
Table 2 Design and key summary findings of experimental studies evaluating N-acetylcysteine in isolated perfused liver models (n = 7)
First author/year Species Experimental model NAC intervention Principal outcome
Vivot et al.
199332
Rat Isolated perfused rat liver with pre,
post and pre&post NAC treatment
groups.
100 mg/kg NAC pre-treatment.
20 mg/dL NAC added to
perfusate in post-treatment.
NAC associated with lower
transaminase in perfusate &
improved bile production.
Dunne et al.
199433
Rat Isolated perfused liver. Sequential cold
and warm ischaemia
100 mg/kg NAC Subcutaneously
prior to hepatectomy 100 mmol/l
in the UW solution and perfusate
NAC induced transient
improvement in
blood and bile flow.
Nakano et al.
199534
Rat Isolated perfused rat liver. 48 h cold &
2 h reperfusion.
intraportal injection of 150 mg/kg
NAC pre-hepatectomy.
NAC enhances hepatocyte
cysteine & has a protective
effect on Kupffer cells.
Nakano et al.
199635
Rat Isolated perfused rat liver after 24 h of
cold storage
Intraportal injection of 150 mg/kg
of NAC with or without
intraperitoneal injection of BSO
before isolation and perfusion
Pre ischemia administration of
NAC attenuated hepatic
injury. Protective effect lost
when NAC at reperfusion.
Nakano et al.
199736
Rat Isolated perfused liver studies (24 h
cold storage 120 min re-perfusion)
and left lobar I/R series (60 min
clamp)
150 mg/kg NAC via mesenteric
vein 15 min before liver harvest.
NAC before cold storage
improved transaminases and
bile production in steatotic
livers.
Nakano et al.
199837
Rat isolated perfused rat liver (24-hour
cold storage in UW followed by
120 min reperfusion.
150 mg/kg NAC via superior
mesenteric vein 15 min before
harvesting
NAC before liver harvesting
might prevent cold I/R
injury in steatotic liver.
(ALT Bile production and liver
tissue GSH)
Nagasaki et al.
199838
Rat isolated perfused liver (cold-storage
48 h and reperfusion for 120 min).
150 mg/kg NAC via superior
mesenteric vein 15 min before
harvesting.
Bile production improved
significantly in the NAC
group.
BSO, L-buthionine-[S,R]-sulfoxamine; ALT, alanine transaminase; GSH, glutathione; NAC, N-acetylcysteine.
Table 3 Design and key summary findings of experimental studies evaluating N-acetylcysteine (NAC) in liver transplantation (n = 4)
First author/year Species Experimental model NAC intervention Principal outcome
Walcher et al.
199539
Rat Livers stored for 20 h in University
of Wisconsin (UW) solution and
transplanted orthotopically
Donors 150 mg/kg NAC PLUS
83 mg/kg NAC at start of
recipient operation.
No change in early microvascular
failure after liver transplantation.
Koeppel et al.
199640
Rat Orthotopic liver transplant
following cold storage in
University of Wisconsin (UW)
solution for 24h
400 mg/kg NAC before
hepatectomy and after
re-perfusion in recipients.
NAC reduced non-perfused
sinusoids and improved bile
flow.
Regueira et al.
199741
Pig Controlled trial of NAC in OLTX 3 g NAC to donor 1 h before warm
ischemia
Reduced SGOT rise, Improved
coagulation, better survival rate
and reduce graft nonfunction.
Manika et al.
199942
Pig RCT of porcine liver OLTX 150 mg/kg NAC infusion to donor
and recipient.
No effect of NAC on liver histology
or graft survival.
OLTX, orthotropic liver transplant; SGOT, serum glutamic oxaloacetic transaminase; RCT, randomized controlled trial.
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Discussion
The present review reports the outcome of a comprehensive
review of studies examining the role of NAC in modulation of I/R
injury associated with major liver surgery and/or transplantation.
Although the authors accept that it is possible that not all reported
work in the field will have been reviewed or cited, the thorough
and reproducible search history makes the present study the most
comprehensive to date on this topic.
There is a wealth of experimental evidence in relation to both
I/R and liver transplantation.
An overview of the experimental studies on liver I/R would be
critical of sample size and the lack of power calculations in allo-
cation of group numbers and also of the lack of pre-defined
primary endpoints. Accepting these limitations, it is accepted that
15 out of the 19 studies examining the role of NAC in liver I/R
injury show a beneficial effect from intervention with positive
outcomes in terms of lower transaminases, reduction in oxidative
injury and lower bacterial translocation. It appears that in order to
be effective, NAC should be administered before induction of I/R
injury. In order to retain a balanced perspective, it should be
acknowledged that 4 of 19 experimental studies in this area show
no positive findings16,19,21,30 and that one of these showed that NAC
reversed the beneficial effects of ischaemic pre-conditioning.19
Similar findings are seen in relation to the role of NAC in the
isolated perfused liver model and in experimental liver transplan-
Table 4 Design and key summary findings of clinical studies evaluating N-acetylcysteine in liver transplantation (n = 9)
First author/year Experimental design NAC intervention Number
treated
with NAC
Number
without
NAC
Endpoint:
Liver
function
Endpoint:
Graft/patient
survival
Bromley et al.
199543
Double-blind,
Placebo-
controlled RCT
Recipient: 150 mg/kg NAC over
15 min followed by 12.5 mg/kg
for 4 h & 6.25 mg/kg for
remainder.
25 25 Higher AST in NAC
group at day 6.
Not reported.
Regueira et
al. 199744
Cohort series:
group receiving
NAC and
group without
NAC.
To donor 6 g NAC iv 1h before
retrieval.
25 37 SGOT: 825.97
control Vs 353.56
NAC
No primary
failure.
Poor graft
function – 5 in
control 0 in
NAC.
Thies et al.
199845
RCT 150 mg/kg before re-perfusion.
Then 50 mg/kg over 4 h.
30 30 AST -NAC
773  133 vs
control
1102  225 U/L
Not reported
Steib et al.
199846
RCT 150 mg/kg NAC over 30 minutes at
SVC anastomosis
Followed by 50 mg/kg for 4 h and
100 mg/kg for 16 h.
30 30 No difference in ALT
or AST.
No difference
Bucuvalas et
al. 200147
Open-label,
non-randomised,
comparative
study
70 mg/kg at reperfusion and
12 hrly for 6 days (in conjunction
with PGE1).
12 13 Peak ALT 499 IU/L
NAC vs 867 IU/L
control.
100% at 3
months in both
groups.
Taut et al.
200148
Non randomized
case-control
150 mg/kg NAC at reperfusion.
50 mg/kg over 4 hours.
100 mg/kg over 16 hours.
9 10 Not reported Not reported
Weigand et
al. 200149
RCT liver flushed with 1l
Ringer's + 1000 mg/L NAC. Plus
150 mg/kg NAC before
reperfusion + continuous infusion
of 50 mg/kg NAC for 4 hr. Then
100 mg/kg NAC 16 hr
10 10 No significant
difference in
serum AST, ALT
and total bilirubin.
Not reported
Khan et al.
200550
RCT Donors: 150 mg/kg NAC before
cardiac arrest
And 75 mg/kg during cold phase.
Recipients did not receive NAC.
9 9 No difference in
trans-aminase.
Not reported.
Santiago et
al. 200851
Double-blind,
Placebo-
controlled RCT
Recipients 100 mg/kg after 15
minutes into anhepatic phase
followed by 50 mg/kg infusion
over 24 h.
25 25 Not reported Not reported
AST = Aspartate transaminase, SGOT = Serum glutamic oxaloacetic transaminase (AST), ALT = Alanine transaminase, ICAM1 = Intercellular adhesion
molecule 1, VCAM1= vascular cell adhesion molecule 1, IL4 = interleukin 4.
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tation. If administered before induction of ischaemia, NAC can
have a beneficial effect in terms of reduction in hepatic injury.
Clinical studies of the use of NAC are almost uniformly of poor
quality. All randomized trials are small in number, with little
evidence of high-quality study markers. In their defence it could
be argued that most of these studies date from over a decade ago
and are from an era when the role of NAC could legitimately be
assessed in small pilot trials. In the context of liver transplanta-
tion, of the nine clinical studies, only three examined graft sur-
vival, and only six reported accepted biochemical indices of injury
and therefore it is possible that more comprehensive studies may
show different outcomes. However, on the available evidence NAC
is unlikely to be of benefit in liver transplantation.
Further evidence for this comes from the study by Hilmi et al.,
although out with the primary search period, this randomized
controlled trial showed that NAC had no effect on hepato-renal
ischaemia or survival in patients undergoing orthotopic liver
transplantation.54
In liver resectional surgery, there is even less evidence to support
the use of N-acetylcysteine. Although the Pringle manoeuvre is
widely used to reduce blood loss during parenchymal transection
and this temporary inflow occlusion is a form of ischaemia reper-
fusion, there is little evidence to support the use of NAC in the
clinical setting. Those units that do currently use this drug in the
post-operative setting do so on the basis of extrapolation from the
experimental evidence. However, it can be seen that the experimen-
tal evidence is not uniform, that studies are contradictory and that
none are powered for direct extrapolation to the clinical setting.
The present report is the most comprehensive review of the role
of NAC in liver surgery to date. There is a wealth of experimental
evidence of the use of NAC in I/R injury and in transplantation.
There appears to be some beneficial effect of NACin terms of a
reduction in experimental liver I/R injury, in particular if the drug
is administered before the onset of the IR injury. Similar benefits
can be seen in the experimental isolated perfused liver scenario.
In conclusion, it would appear that N-acetylcysteine, given
before induction of liver I/R injury in an experimental model, may
have a positive effect on markers of liver injury. Currently, there
remains little evidence that this effect translates in a positive
fashion to any clinically relevant end point either in liver trans-
plantation or in liver resectional surgery.
Conflict of interest
None declared.
References
1. Laca L, Olejnik J, Vician M, Grandtnerova B, Zahradnik V. (2006) The
effects of occlusive techniques on the short-term prognosis after liver
resections. Hepatogastroenterology 53:576–579.
2. Kretzschmar M, Kruger A, Schirrmeister W. (2003) Hepatic ischemia-
reperfusion syndrome after partial liver resection (LR): hepatic venous
oxygen saturation, enzyme pattern, reduced and oxidized glutathione,
procalcitonin and interleukin-6. Exp Toxicol Pathol 54:423–431.
3. Serracino-Inglott F, Habib NA, Mathie RT. (2001) Hepatic ischemia-
reperfusion injury. Am J Surg 181:160–166.
4. Lander HM. (1997) An essential role for free radicals and derived species
in signal transduction. FASEB J 11:118–124.
5. Yu BP. (1994) Cellular defences against damage from reactive oxygen
species. Physiol Rev 74:139–162.
6. Davis W Jr, Ronai Z, Tew KD. (2001) Cellular thiols and reactive
oxygen species in drug induced apoptosis. J Pharmacol Exp Ther
296:1–6.
7. Zafarullah M, Li WQ, Sylvester J, Ahmad M. (2003) Molecular mecha-
nisms of N-acetylcysteine actions. Cell Mol Life Sci 60:6–20.
8. Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT.
(1977) Treatment of paracetamol (acetaminophen) poisoning with
N-acetylcysteine. Lancet 27:432–434.
9. Prescott LF, Illingworth RN, Critchley JA, Proudfoot AT. (1980) Intrave-
nous N-acetylcysteine: still the treatment of choice for paracetamol poi-
soning. BMJ 5:46–47.
10. Makin AJ, Wendon J, Williams R. (1995) A 7 year experience of severe
acetaminophen-induced hepatotoxicity (1987–1993). Gastroenterology
109:1907–1916.
11. Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ
et al. (1991) Intravenous acetylcysteine in paracetamol induced fulminant
hepatic failure: a prospective controlled trial. BMJ 26:1026–1029.
12. Ryan R, Hill S, Broclain D, Horey D, Oliver S, Prictor M, Cochrane
Consumers and Communication Review Group. Study Quality
Guide. March 2007. http://www.latrobe.edu.au/cochrane/resources.html
(accessed on 26/03/2010).
13. Fukuzawa K, Emre S, Senyuz O, Acarli K, Schwartz ME, Miller CM. (1995)
N-acetylcysteine ameliorates reperfusion injury after warm hepatic
ischemia. Transplantation 59:6–9.
14. Koeppel TA, Thies JC, Lehmann T, Gebhard MM, Herfarth C, Otto G et al.
(1996) Improvement of hepatic microhemodynamics by N-acetylcysteine
after warm ischemia. Eur Surg Res 28:270–277.
15. Demir S, Inal-Erden M. (1998) Pentoxifylline and N-acetylcysteine in
hepatic ischemia/reperfusion injury. Clin Chim Acta 28:127–135.
16. Chavez-Cartaya R, Jamieson NV, Ramireza P, Marina J, Pino-Chaveza G.
(1999) Free radical scavengers to prevent reperfusion injury following
warm liver ischemia. Transplant Proc 31:2439–2440.
17. Hur GM, Ryu YS, Yun HY, Jeon BH, Kim YM, Seok JH et al. (1999)
Hepatic ischemia/reperfusion in rats induces iNOS gene transcription by
activation of NF-kappaB. Biochem Biophys Res Commun 261:917–922.
18. Sener G, Tosun O, Sehirli AO, Kacmaz A, Arbak S, Ersoy Y et al. (2003)
Melatonin and N-acetylcysteine have beneficial effects during hepatic
ischemia and reperfusion. Life Sci 72:2707–2718.
19. Rudiger HA, Graf R, Clavien PA. (2003) Sub-lethal oxidative stress trig-
gers the protective effects of ischemic preconditioning in the mouse liver.
J Hepatol 39:972–977.
20. Glantzounis GK, Yang W, Koti RS, Mikhailidis DP, Seifalian AM, Davidson
BR. (2004) Continuous infusion of N-acetylcysteine reduces liver warm
ischaemia-reperfusion injury. Br J Surg 91:1330–1339.
21. Montero EFS, Quireze Jr C, D'Oliveira DMR. (2005) Bile duct exclusion
from selective vascular inflow occlusion in rat liver: role of ischemic
preconditioning and N-acetylcysteine on hepatic reperfusion injury.
Transplant Proc 37:425–427.
22. Okay E, Karadenizli A, Muezzinoglu B, Zeybek U, Ergen HA, Isbir T. (2005)
N-acetylcysteine attenuates bacterial translocation after partial hepatec-
tomy in rats. J Surg Res 127:164–170.
HPB 77
HPB 2011, 13, 71–78 © 2011 International Hepato-Pancreato-Biliary Association
23. Smyrniotis V, Arkadopoulos N, Kostopanagiotou G, Theodoropoulos T,
Theodoraki K, Farantos C et al. (2005) Attenuation of ischemic injury by
N-acetylcysteine preconditioning of the liver. J Surg Res 129:31–37.
24. Fusai G, Glantzounis GK, Hafez T, Yang W, Quaglia A, Sheth H et al.
(2005) N-acetylcysteine ameliorates the late phase of liver ischaemia/
reperfusion injury in the rabbit with hepatic steatosis. Clin Sci 109:465–
473.
25. Chen C-F, Leu FJ, Chen HI, Wang D. (2005) Oxygen radicals and matrix
metalloproteinases mediate reperfusion liver injury. Transplant Proc
37:4547–4549.
26. Glantzounis GK, Rocks SA, Sheth H, Knight I, Salacinski HJ, Davidson
BR et al. (2007) Formation and role of plasma S-nitrosothiols in liver
ischemia-reperfusion injury. Free Radic Biol Med 42:882–892.
27. Jin X, Wang L, Wu HS, Zhang L, Wang CY, Tian Y et al. (2007)
N-acetylcysteine inhibits activation of toll-like receptor 2 and 4 gene
expression in the liver and lung after partial hepatic ischemia-reperfusion
injury in mice. Hepatobiliary Pancreat Dis Int 6:284–289.
28. Oz S, Okay E, Karadenizli A, Cekmen MB, Ozdogan HK. (2007)
N-acetylcysteine improves intestinal barrier in partially hepatectomized
rats. ANZ J Surg 77:173–176.
29. Galhardo MA, Quireze JC, Navarro PGR, Morello RJ, Simoes MDJ,
Montero EFDS. (2007) Liver and lung late alterations following hepatic
reperfusion associated to ischemic preconditioning or N-acetylcysteine.
Microsurgery 27:295–299.
30. Baumann J, Ghosh S, Szakmany T, Jancso G, Ferencz A, Roth E et al.
(2008) Short-term effects of N-acetylcysteine and ischemic precondition-
ing in a canine model of hepatic ischemia-reperfusion injury. Eur Surg
Res 41:226–230.
31. Keles MS, Demirci N, Yildirim A, Atamanalp SS, Altinkaynak K. (2008)
Protective effects of N-acetylcysteine and Ginkgo biloba extract on
ischaemia-reperfusion-induced hepatic DNA damage in rats. Clin Exp
Med 8:193–198.
32. Vivot C, Stump DD, Schwartz ME, Theise ND, Miller CM. (1993)
N-acetylcysteine attenuates cold ischemia/reperfusion injury in the iso-
lated perfused rat liver. Transplant Proc 25:1983–1984.
33. Dunne JB, Davenport M, Williams R, Tredger JM. (1994) Evidence that
S-adenosylmethionine and N-acetylcysteine reduce injury from sequen-
tial cold and warm ischemia in the isolated perfused rat liver. Transplan-
tation 57:1161–1168.
34. Nakano H, Boudjema K, Alexandre E, Imbs P, Chenard MP, Wolf P et al.
(1995) Protective effects of N-acetylcysteine on hypothermic ischemia-
reperfusion injury of rat liver. Hepatology 22:539–545.
35. Nakano H, Boudjema K, Jaeck D, Alexandre E, Imbs P, Chenard MP et al.
(1996) Amelioration of hepatocellular integrity and inhibition of sinusoidal
oxidative stress by n-acetylcysteine pretreatment in cold ischemia-
reperfusion injury of rat liver. Eur Surg Res 28:245–255.
36. Nakano H, Nagasaki H, Barama A, Boudjema K, Jaeck D, Kumada K
et al. (1997) The effects of N-acetylcysteine and anti-intercellular adhe-
sion molecule-1 monoclonal antibody against ischemia-reperfusion injury
of the rat steatotic liver produced by a choline-methionine-deficient diet.
Hepatology 26:670–678.
37. Nakano H, Nagasaki H, Yoshida K, Kigawa G, Fujiwara Y, Kitamura N
et al. (1998) N-acetylcysteine and anti-ICAM-1 monoclonal antibody
reduce ischemia-reperfusion injury of the steatotic rat liver. Transplant
Proc 30:3763–3763.
38. Nagasaki H, Nakano H, Boudjema K, Jaeck D, Alexandre E, Baek Y et al.
(1998) Efficacy of preconditioning with N-acetylcysteine against reperfu-
sion injury after prolonged cold ischaemia in rats liver in which glutathione
had been reduced by buthionine sulphoximine. Eur J Surg 164:139–146.
39. Walcher E, Marzi I, Flecks U, Larsen R. (1995) N-acetylcysteine failed to
improve early microcirculatory alterations of the rat liver after transplan-
tation. Transpl Int 8:317–323.
40. Koeppel TA, Lehmann TG, Thies JC, Gehrcke R, Gebhard MM, Herfarth
C et al. (1996) Impact of N-acetylcysteine on the hepatic microcirculation
after orthotopic liver transplantation. Transplantation 61:1397–1402.
41. Regueira FM, Hernández JL, Sola I, Cienfuegos JA, Pardo F,
Díez-Caballero A et al. (1997) Ischemic damage prevention by
N-acetylcysteine treatment of the donor before orthotopic liver transplan-
tation. Transplant Proc 29:3347–3349.
42. Manika A, Trinh T, Lagace G, Dugas MA, Proulx F, Lepage G et al. (1999)
N-acetylcysteine in pig liver transplantation from non-heart-beating
donors. Transplantation 68:327–330.
43. Bromley PN, Cottam SJ, Hilmi I, Tan KC, Heaton N, Ginsburg R et al.
(1995) Effects of intraoperative N-acetylcysteine in orthotopic liver trans-
plantation. Br J Anaesthesia 75:352–354.
44. Regueira FM, Hernandez JL, Sola I, Cienfuegos JA, Pardo F, Diez-
Caballero A et al. (1997) Ischemic damage prevention by
N-acetylcysteine treatment of the donor before orthotopic liver transplan-
tation. Transplant Proc 29:3347–3349.
45. Thies JC, Teklote J, Clauer U, Tox U, Klar E, Hofmann WJ et al. (1998) The
efficacy of N-acetylcysteine as a hepatoprotective agent in liver trans-
plantation. Transpl Int 11:S390–S392.
46. Steib A, Freys G, Collin F, Launoy A, Mark G, Boudjema K. (1998) Does
N-acetylcysteine improve hemodynamics and graft function in liver trans-
plantation. Liver Transpl Surg 4:152–157.
47. Bucuvalas JC, Ryckman FC, Krug S, Alonso MH, Balistreri WF, Kotagal
U. (2001) Effect of treatment with prostaglandin E and N-acetylcysteine
on pediatric liver transplant recipients: a single-center study. Pediatr
Transplant 5:274–278.
48. Taut FJ, Schmidt H, Zapletal CM, Thies JC, Grube C,Motsch J et al. (2001)
N-acetylcysteine induces shedding of selectins from liver and intestine
during orthotopic liver transplantation. Clin Exp Immunol 124:337–334.
49. Weigand MA, Plachky J, Thies JC, Spies-Martin D, Otto G, Martin E et al.
(2001) N-acetylcysteine attenuates the increase in alpha-glutathione
S-transferase and circulating ICAM-1 and VCAM-1 after reperfusion in
humans undergoing liver transplantation. Transplantation 72:694–698.
50. Khan AW, Fuller BJ, Shah SR, Davidson BR, Rolles K. (2005) A prospec-
tive randomized trial of N-acetylcysteine administration during cold pres-
ervation of the donor liver for transplantation. Ann Hepatol 4:121–126.
51. Santiago FM, Bueno P, Olmedo C, Muffak-Granero K, Comino A, Serra-
dilla M et al. (2008) Effect of N-acetylcysteine Administration on Intraop-
erative Plasma Levels of Interleukin-4 and Interleukin-10 in Liver
Transplant Recipients. Transplant Proc 40:2978–2980.
52. Sheth H, Glantzounis G, Hafez T, Quaglia A, Duncan J, Davidson BR.
(2005) Does perioperative N-acetylcysteine prevent ischemia reperfusion
injury during liver resection? Gut 54 (Suppl 2):148.
53. Szakmany T, Marton S, Molnar Z. (2003) Lack of effect of prophylactic
N-acetylcysteine on postoperative organ dysfunction following major
abdominal tumour surgery: a randomized, placebo-controlled, double-
blinded clinical trial. Anaesth Intensive Care 31:267–271.
54. Hilmi IA, Peng Z, Planinsic RM, Damian D, Dai F, Tyurina YY et al.
(2010) N-acetylcysteine does not prevent hepatorenal ischaemia–
reperfusioninjury in patients undergoing orthotopic liver transplantation.
Nephrol Dial Transplant 25:2328–2333.
78 HPB
HPB 2011, 13, 71–78 © 2011 International Hepato-Pancreato-Biliary Association
